Physician profile
Marvin Grieff
NPI 1477500619
$2,168.42
in general payments reported to CMS, 2019-2025
10 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2021: $16.19 · 2022: $139 · 2023: $129 · 2024: $286 · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,052 · Food and Beverage: $655 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,051.57 |
| Food and Beverage | $654.54 |
| Education | $190.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $1,324.17 | 2025 | Renal - Chronic |
| Travere Therapeutics, INC. | $190.30 | 2023-2025 | Filspari, Thiola |
| Amgen INC. | $133.58 | 2019-2025 | Tavneos |
| Sanofi-Aventis U.S. LLC | $124.99 | 2023 | |
| Ardelyx, INC. | $122.78 | 2024 | Xphozah 30 Mg |
| Glaxosmithkline, LLC. | $112.32 | 2022 | |
| Veloxis Pharmaceuticals, INC. | $78.83 | 2019 | |
| Baxter Healthcare | $42.91 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $22.55 | 2019 | |
| Calliditas Therapeutics US INC. | $15.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Grieff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.